Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia

PURPOSE: While significant progress has been made in the treatment of T-cell acute lymphoblastic leukemia (T-ALL), many patients will require additional therapy for relapsed/refractory disease. Cyclin D3 (CCND3) and CDK6 are highly expressed in T-ALL and have been effectively targeted in mutant NOTC...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Pikman, Yana, Alexe, Gabriela, Roti, Giovanni, Conway, Amy Saur, Furman, Andrew, Lee, Emily S., Place, Andrew E., Kim, Sunkyu, Saran, Chitra, Modiste, Rebecca, Weinstock, David M., Harris, Marian, Kung, Andrew L., Silverman, Lewis B., Stegmaier, Kimberly
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5432118/
https://ncbi.nlm.nih.gov/pubmed/28151717
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2869
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados